// archives

phase 1 investor

This tag is associated with 5 posts

1,400% Gains from Iraqi Oil, Part Two

By StockGumshoe ⋅ July 27, 2009 ⋅ 15 comments

Late last week I wrote about a new teaser from the Phase 1 newsletter at Stansberry & Associates — as far as these things go it’s actually a relatively low-hype, fact-based teaser ad, since there’s a pretty big fundamental argument in favor of anyone who can profit from Iraq’s oil reserves (as well as lots [...]

Iraqi Oil: “The Most Dangerous 1,400%+ You’ll Ever See?”

By StockGumshoe ⋅ July 23, 2009 ⋅ 13 comments

This ad is getting a lot of attention from my readers, if my inbox is any indication — it’s for the Phase 1 Investor service from Stansberry & Associates, which is their expensive premium letter that has historically focused mostly on biotech stocks but is also used by them for any super-tiny stocks that would [...]

A Good Old Fashioned Newsletter Fight

By StockGumshoe ⋅ February 21, 2009 ⋅ 14 comments

I don’t see this very often, but it looks like there’s a little battle brewing between Ian Cooper and Rob Fannon … or probably more precisely, between Stansberry & Associates and Angel Publishing.
I don’t know if this has anything to do with it, but the two seem linked in several “sincerest form of [...]

Magic Pill? “This is the kind of situation that can change your life …”

By StockGumshoe ⋅ February 4, 2009 ⋅ 41 comments

Stansberry & Associates’ Phase 1 Investor newsletter is teasing us about shares of a drug company: “On March 30, FDA results we’ve waited 2 years to receive could make you $195,600, overnight” — and they quote Porter Stansberry as saying that “This is the kind of situation that can change your life… where a $10,000 stake can allow you to literally quit work, forever.” Sounds nice, eh?

“Don’t Let this 10-Bagger Pass You By” Phase 1 Investor

By StockGumshoe ⋅ October 21, 2008 ⋅ 20 comments

I haven’t written much about Rob Fannon and his Phase 1 Investor newsletter lately — this is the high end newsletter published by the folks at Stansberry and Associates, it’ll run you about $4,500 a year, and it’s largely focused on biotech companies.
So is their advice worth more than the advice from less [...]

“L-2 Indicator: Best for Gold Stocks”

By StockGumshoe ⋅ January 30, 2008 ⋅ 18 comments

This teaser comes in from the folks at Stansberry’s Phase 1 Investor service, which is their uber-expensive $5,000 subscription newsletter that purports to find the best opportunities in the smallest stocks.
They have developed what they call the L-2 Indicator that tells them when to buy stocks, in this case gold stocks: “the ‘L-2 Indicator’ [...]

"Gen-dx Test Predicts Cancer"

By StockGumshoe ⋅ December 7, 2007 ⋅ One comment

This teaser and the solution come in from our old friend Streetsifter, who has written up a few solutions in this space in the past — t0 the great appreciation of your Gumshoe. His solution has been confirmed by a few other readers who I know do a good job sniffing out solutions, so [...]

"Jack Morgan’s Single Best Investment for 2007"

By StockGumshoe ⋅ April 27, 2007 ⋅ 20 comments

So that’s an attention-getting claim, eh?
Wait, it gets better.
This one comes to us from Porter Stansberry at Phase 1 Investor, who would like us to pony up … get ready for it … $5,000 for entry into the exclusive group of investors who are going to find out — in a report released today, Friday [...]

"New FDA-approved medical device could make you rich"

By StockGumshoe ⋅ March 27, 2007 ⋅ 6 comments

This one comes to us from Peter Stansberry as part of an ad for his Phase 1 Investor service … which he’d like you to subscribe to in exchange for learning about this fabulous company in a special report.
In fact, he’s promising that his biotech analyst will reveal the name of this company on Thursday [...]

—

Archives